Pipeline
DISIT Biotech is Developing a Pipeline of Preventive Solutions for Radiation-Induced Fibrosis for the Two Most Common Cancers Globally.
DISITERTIDE Systemic Formulation
Indication: Radiation-induced Lung Fibrosis
Development Stage: Preclinic
DISITERTIDE’s optimized systemic formulation stands at the vanguard of DISIT Biotech’s asset portfolio.
It is developed to deliver a potent, systemic preventive effect, addressing a critical need in the management of radiation-induced fibrosis in lung cancer.
As the flagship asset, its systemic approach promises to redefine treatment standards with its heightened efficacy.
DISITERTIDE Topical Formulation
Indication: Radiation-induced Breast Fibrosis
Development Stage: Preclinic
The topical formulation of DISITERTIDE, although further along the development pathway, serves as an adjunct asset with strategic potential.
It offers a direct, localized treatment for radiation-induced breast fibrosis, either as a standalone or complementing the systemic formulation.
Its future development will cater to specific fibrotic conditions, enhancing the company’s fibrosis care suit
